Alexander Dimitrios Colevas, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Colevas’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C52711 · Current
Licensed to practise in California · since 2007 · expires 2026-11-30 · Johns Hopkins University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$121,939
Medicare paid this office $121,939 for 258 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 161 | $75,803 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $10,113 | $106 |
| New patient visit (60+ min) | 44 | $7,159 | $163 |
| Return visit (30+ min) | 46 | $5,974 | $83 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 116 | $5,842 | $15 |
See all 9 services
| Long return visit (40+ min) | 161 | $75,803 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $10,113 | $106 |
| New patient visit (60+ min) | 44 | $7,159 | $163 |
| Return visit (30+ min) | 46 | $5,974 | $83 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 116 | $5,842 | $15 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $4,978 | $156 |
| Diagnostic exam of voice box using a flexible endoscope | 43 | $3,666 | $61 |
| Return visit (30+ min) | 18 | $3,201 | $110 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,154 | $105 |
Who their Medicare patients are
258 Original Medicare patients in 2024. Average age 74 · Under 65 8% · 85 and older 9% · Women 34% · Also on Medicaid 24% · Health risk score 2.45. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 68% · Coronary heart disease 29% · Diabetes 25% · Chronic kidney disease 24% · Cancer 22% · Atrial fibrillation 21% · Heart failure 19% · Depression 19% · COPD 16% · Stroke 10% · Dementia 6%.
The office billed $303,165, Medicare allowed $158,207 and paid $121,939; for 1,396 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 258 | 1,396 | 74 | 2.45 | $303,165 | $121,939 |
| 2023 | 194 | 681 | 74 | 2.36 | $174,512 | $80,569 |
| 2022 | 231 | 871 | 73 | 2.23 | $199,672 | $100,373 |
| 2021 | 193 | 712 | 73 | 2.34 | $159,840 | $82,738 |
| 2020 | 211 | 995 | 72 | 2.40 | $210,682 | $93,235 |
| 2019 | 302 | 1,279 | 72 | 2.43 | $242,265 | $117,440 |
| 2018 | 313 | 1,291 | 71 | 2.16 | $230,926 | $123,142 |
| 2017 | 260 | 1,056 | 72 | 2.14 | $274,612 | $99,545 |
| 2016 | 233 | 941 | 72 | 2.40 | $275,084 | $90,160 |
| 2015 | 275 | 876 | 71 | 2.20 | $265,569 | $85,864 |
| 2014 | 212 | 846 | 71 | 1.97 | $242,008 | $80,170 |
| 2013 | 200 | 902 | 71 | 2.07 | $271,498 | $82,653 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Long return visit (40+ min) | 115 | $48,434 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $9,763 | $110 |
| Return visit (30+ min) | 45 | $6,865 | $90 |
| New patient visit (60+ min) | 29 | $4,676 | $161 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,638 | $160 |
| Diagnostic exam of voice box using a flexible endoscope | 39 | $2,774 | $63 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,178 | $107 |
2022: 6 services
| Long return visit (40+ min) | 166 | $72,154 | $125 |
| Return visit (30+ min) | 43 | $6,587 | $86 |
| New patient visit (60+ min) | 37 | $6,251 | $169 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,407 | $176 |
| Diagnostic exam of voice box using a flexible endoscope | 41 | $3,748 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $2,694 | $90 |
2021: 6 services
| Long return visit (40+ min) | 137 | $58,006 | $129 |
| Return visit (30+ min) | 55 | $6,718 | $85 |
| New patient visit (60+ min) | 30 | $5,240 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $4,009 | $95 |
| Diagnostic exam of voice box using a flexible endoscope | 39 | $3,162 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,637 | $188 |
2020: 8 services
| Long return visit (40+ min) | 154 | $63,255 | $100 |
| Return visit (30+ min) | 78 | $10,030 | $70 |
| New patient visit (60+ min) | 34 | $5,204 | $153 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $4,304 | $98 |
| Diagnostic exam of voice box using a flexible endoscope | 44 | $3,218 | $55 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,320 | $193 |
| Return visit (30+ min) | 18 | $1,326 | $66 |
| Short return visit (20+ min) | 13 | $731 | $49 |
2019: 7 services
| Long return visit (40+ min) | 215 | $78,135 | $95 |
| New patient visit (60+ min) | 64 | $9,422 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $8,584 | $94 |
| Return visit (30+ min) | 49 | $6,460 | $69 |
| Diagnostic exam of voice box using a flexible endoscope | 81 | $5,996 | $55 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,120 | $184 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,190 | $99 |
2018: 6 services
| Long return visit (40+ min) | 214 | $80,426 | $96 |
| New patient visit (60+ min) | 103 | $15,216 | $148 |
| Diagnostic exam of voice box using a flexible endoscope | 86 | $7,584 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $7,115 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,548 | $182 |
| Return visit (30+ min) | 43 | $4,521 | $70 |
2017: 7 services
| Long return visit (40+ min) | 172 | $62,774 | $96 |
| New patient visit (60+ min) | 83 | $11,982 | $144 |
| Diagnostic exam of voice box using a flexible endoscope | 70 | $7,991 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $6,760 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,743 | $176 |
| Return visit (30+ min) | 20 | $1,552 | $67 |
| Hospital discharge day management, 30 minutes or less | 13 | $861 | $66 |
2016: 6 services
| Long return visit (40+ min) | 154 | $59,100 | $95 |
| New patient visit (60+ min) | 62 | $8,665 | $140 |
| Diagnostic exam of voice box using a flexible endoscope | 57 | $6,395 | $70 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $5,768 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $5,555 | $93 |
| Return visit (30+ min) | 17 | $1,611 | $70 |
2015: 8 services
| Long return visit (40+ min) | 165 | $45,642 | $96 |
| New patient visit (60+ min) | 74 | $10,860 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 38 | $10,514 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $6,331 | $181 |
| Diagnostic exam of voice box using a flexible endoscope | 52 | $4,919 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,294 | $65 |
| Return visit (30+ min) | 18 | $1,263 | $66 |
| Hospital discharge day management, 30 minutes or less | 17 | $1,193 | $66 |
2014: 6 services
| Long return visit (40+ min) | 144 | $48,094 | $94 |
| New patient visit (60+ min) | 83 | $12,258 | $148 |
| Diagnostic exam of voice box using a flexible endoscope | 62 | $7,865 | $71 |
| Return visit (30+ min) | 29 | $3,411 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $3,142 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,338 | $180 |
2013: 7 services
| Long return visit (40+ min) | 120 | $41,891 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $11,893 | $89 |
| New patient visit (60+ min) | 58 | $8,324 | $144 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,280 | $174 |
| Diagnostic exam of voice box using a flexible endoscope | 43 | $5,362 | $69 |
| Return visit (30+ min) | 33 | $3,136 | $63 |
| Hospital discharge day management, 30 minutes or less | 13 | $893 | $64 |
Medicaid work
$7,464 in 2024
Medicaid paid $7,464 for 120 billed services this clinician did in 2024, up to 21 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 120 | $7,464 |
| 2024 | 120 | 1 | 21 | $7,464 |
| 2023 | 207 | 1 | 21 | $9,555 |
| 2022 | 331 | 2 | 24 | $14,383 |
| 2021 | 214 | 2 | 22 | $11,506 |
| 2020 | 180 | 1 | 21 | $8,532 |
| 2019 | 327 | 1 | 30 | $13,327 |
| 2018 | 367 | 1 | 28 | $19,814 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 207 | $9,555 |
2022
| Long return visit (40+ min) | 317 | $13,429 |
| 1ST HOSP IP/OBS HIGH 75 | 14 | $953 |
2021
| Long return visit (40+ min) | 178 | $8,754 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 36 | $2,752 |
2020
| Long return visit (40+ min) | 180 | $8,532 |
2019
| Long return visit (40+ min) | 327 | $13,327 |
2018
| Long return visit (40+ min) | 367 | $19,814 |
Drugs they prescribed that Part D paid
$1,217,616
Pharmacies billed $1,217,616 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 6% of their Part D prescriptions (21 of 374) in 2024. At or below the middle of the specialty; the typical medical oncology clinician is at 6%.
259 generic and fewer than 11 brand-name prescriptions · $1,217,616 in drug cost · 16 antibiotic prescriptions to 13 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lenvima | 20 | $463,727 | $23,186 |
| Eliquis | 19 | $10,835 | $570 |
| Gabapentin | 22 | $590 | $27 |
| Ondansetron | 15 | $562 | $37 |
| Levothyroxine | 40 | $243 | $6 |
See all 7 drugs
| Lenvima | 20 | $463,727 | $23,186 |
| Eliquis | 19 | $10,835 | $570 |
| Gabapentin | 22 | $590 | $27 |
| Ondansetron | 15 | $562 | $37 |
| Levothyroxine | 40 | $243 | $6 |
| Dexamethasone | 16 | $208 | $13 |
| Prochlorperazine Maleate | 11 | $132 | $12 |
Year by year
| 2024 | 374 | 87 | 6% (21) | None | $1,217,616 |
| 2023 | 169 | 47 | None | None | $498,877 |
| 2022 | 101 | 46 | None | None | $403,276 |
| 2021 | 75 | 31 | None | 31% | $136,672 |
| 2020 | 143 | 43 | None | 36% | $578,153 |
| 2019 | 288 | 67 | 10% (28) | 39% | $916,409 |
| 2018 | 176 | 54 | None | 19% | $188,155 |
| 2017 | 213 | 61 | 15% (32) | 19% | $170,924 |
| 2016 | 217 | 64 | 19% (42) | 18% | $109,683 |
| 2015 | 210 | 72 | 16% (34) | 10% | $35,799 |
| 2014 | 253 | 55 | 10% (26) | 9% | $81,606 |
| 2013 | 228 | 59 | 16% (36) | 19% | $112,871 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Lenvima | 11 | $251,582 | $22,871 |
| Levothyroxine | 29 | $281 | $10 |
2022: 2 drugs
| Lenvima | 13 | $280,678 | $21,591 |
| Prednisone | 13 | $101 | $8 |
2020: 3 drugs
| Lenvima | 17 | $336,386 | $19,787 |
| Ondansetron | 17 | $504 | $30 |
| Prochlorperazine Maleate | 12 | $217 | $18 |
2019: 5 drugs
| Mekinist | 23 | $278,556 | $12,111 |
| Lenvima | 14 | $263,132 | $18,795 |
| Tafinlar | 22 | $223,224 | $10,147 |
| Levothyroxine | 38 | $493 | $13 |
| Ondansetron | 18 | $340 | $19 |
2018: 4 drugs
| Ondansetron | 18 | $410 | $23 |
| Levothyroxine | 14 | $211 | $15 |
| Dexamethasone | 14 | $143 | $10 |
| Prochlorperazine Maleate | 14 | $66 | $5 |
2017: 4 drugs
| Ondansetron | 17 | $4,308 | $253 |
| Levothyroxine | 19 | $314 | $17 |
| Lorazepam | 17 | $56 | $3 |
| Prochlorperazine Maleate | 12 | $55 | $5 |
2016: 5 drugs
| Hydrocodone-Acetaminophen | 11 | $546 | $50 |
| Levothyroxine | 14 | $154 | $11 |
| Gabapentin | 12 | $102 | $9 |
| Prochlorperazine Maleate | 13 | $66 | $5 |
| Lorazepam | 13 | $53 | $4 |
2015: 3 drugs
| Ondansetron | 17 | $919 | $54 |
| Prochlorperazine Maleate | 12 | $64 | $5 |
| Lorazepam | 14 | $52 | $4 |
2014: 7 drugs
| Enoxaparin | 29 | $14,248 | $491 |
| Ondansetron | 25 | $595 | $24 |
| Dexamethasone | 20 | $136 | $7 |
| Prochlorperazine Maleate | 23 | $131 | $6 |
| Levothyroxine | 11 | $119 | $11 |
| Lorazepam | 19 | $83 | $4 |
| Metoclopramide | 16 | $64 | $4 |
2013: 6 drugs
| Ondansetron | 11 | $382 | $35 |
| Gabapentin | 15 | $377 | $25 |
| Hydrocodone-Acetaminophen | 27 | $245 | $9 |
| Levothyroxine | 18 | $199 | $11 |
| Prochlorperazine Maleate | 11 | $91 | $8 |
| Lorazepam | 11 | $48 | $4 |
Money from drug and device companies
$117 in 2025
| 2025 | 1 | 1 | None | $117 |
| 2023 | 1 | 1 | None | $92 |
| 2020 | 2 | 2 | $3,610 | $3,634 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Aveo Pharmaceuticals | Fotivda | $117 | 1 payment
|
See the published payment
| Aveo Pharmaceuticals | Meals · 2025-06-01 | Fotivda | $117 |
See earlier years (2023, 2020)
2023: $92
| Genmab U.S. | Epkinly | $92 | 1 payment
|
2020: $3,634
| Gilead Sciences | None | $3,610 | 1 payment
|
| Eisai | Lenvima | $24 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Innate Pharma, Inc · Study of Iph2201 (Monalizumab) and Cetuximab in Patients With Recurrent Or Metastatic Squamous Cell Carcinoma of the Head and Neck · 2020 | Their institution | $1,383,992 |
| AbbVie Inc. · 2020 | Their institution | $458,342 |
| Coherus Oncology, Inc. · 2025 | Their institution | $280,108 |
| Coherus Biosciences Inc. · 2024 | Their institution | $136,590 |
| Merck Sharp & Dohme Corporation · An Open-Label Phase 1b,2 Study To Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-Pretreated, Recurrent,Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinomaallogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes Ata129 in Combination With Checkpoint Inhibitor Pembrolizumab in Patients With Advanced Platinum-Resistant Or Refractory Ebv-Associated Nasopharyngeal Carcinoma · 2019 | Their institution | $124,200 |
| Gilead Sciences, Inc. · A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma · 2021 | Their institution | $122,464 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l H&N Metastatic Nivo Chemo · 2019 | Their institution | $113,832 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l H&N Metastatic Nivo Chemo · 2020 | Their institution | $96,988 |
| E.R. Squibb & Sons, L.L.C. · Phase III Head & Neck 2l Registrational · 2020 | Their institution | $94,770 |
| Exelixis Inc. · A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib Xl184 in Subjects With Radioiodine Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vegfr-Targeted Therapy · 2021 | Their institution | $93,331 |
| AbbVie, Inc. · 2019 | Their institution | $90,407 |
| BioNTech SE · 2022 | Their institution | $82,896 |
| Merck Sharp & Dohme LLC · A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of Cue-101 Monotherapy in Second Line Or Cue-101 Combination Therapy With Pembrolizumab in First Line Patients With Hpv Recurrent,Metastatic Head and Neck Squamous Cell Carcinoma Hnscc · 2022 | Their institution | $78,100 |
| BioNTech SE · 2021 | Their institution | $76,716 |
| Exelixis Inc. · A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib Xl184) in Subjects With Radioiodine Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vegfr-Targeted Therapy · 2020 | Their institution | $62,916 |
| ABBVIE INC. · A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of Abbv-368 As A Single Agent and Combination in Subjects With Locally Advanced Or Metastatic Solid Tumors · 2021 | Their institution | $48,387 |
| E.R. Squibb & Sons, L.L.C. · Phase III Head & Neck 2l (Registrational) - An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab Vs Therapy of Investigator'S Choice in Recurrent Or Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck (Scchn) · 2023 | Their institution | $44,262 |
| Incyte Corporation · Phase 2, Open-Label, Multicenter Study of Incagn01876 in Combination With Immunotherapy in Participants With Recurrent Or Metastatic Head and Neck Squamous Cell Carcinoma · 2023 | Their institution | $43,488 |
| AstraZeneca UK Limited · This Is A Randomized Open Label Multi Center Global Phase III Study To Determine the Efficacy and Safety of Medi4736 As Monotherapy and Medi4736 Tremelimumab Combination Therapy Versus Soc Therapy in the Target Patient Population · 2019 | Their institution | $35,325 |
| ABBVIE INC. · First in Human Study With Abbv-Cls-579 When Given Alone Or in Combination With Programmed Cell Death-1 Inhibitor in Participants With Locally Advanced Or Metastatic Tumors · 2024 | Their institution | $32,438 |
| Merck Sharp & Dohme LLC · A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of Cue-101 Monotherapy in Second Line Or Cue-101 Combination Therapy With Pembrolizumab in First Line Patients With Hpv Recurrent,Metastatic Head and Neck Squamous Cell Carcinoma Hnscc · 2024 | Their institution | $31,520 |
| BioNTech SE · Pre-Commercial · 2023 | Their institution | $27,633 |
| Merck Sharp & Dohme Corporation · A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of Cue-101 Monotherapy in Second Line Or Cue-101 Combination Therapy With Pembrolizumab in First Line Patients With Hpv Recurrent,Metastatic Head and Neck Squamous Cell Carcinoma Hnscc · 2020 | Their institution | $26,000 |
| E.R. Squibb & Sons, L.L.C. · Phase III Head & Neck 2l Registrational · 2019 | Their institution | $21,327 |
| Exelixis Inc. · A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib (Xl184) in Subjects With Radioiodine Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vegfr-Targeted Therapy · 2022 | Their institution | $19,635 |
| Exelixis Inc. · A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib Xl184 in Subjects With Radioiodine Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vegfr-Targeted Therapy · 2019 | Their institution | $17,278 |
| BioNTech SE · 2024 | Their institution | $14,336 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l H&N Metastatic Nivo Chemo · 2021 | Their institution | $12,328 |
| E.R. Squibb & Sons, L.L.C. · Phase III Head & Neck 2l Registrational · 2021 | Their institution | $9,550 |
| E.R. Squibb & Sons, L.L.C. · Phase III Head & Neck 2l Registrational - An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab Vs Therapy of Investigator'S Choice in Recurrent Or Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck (Scchn) · 2022 | Their institution | $6,165 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l H&N Metastatic (Nivo/Chemo) - An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin+Fluorouracil) As First Line Therapy in Recurrent Or M · 2023 | Their institution | $5,056 |
| Exelixis Inc. · A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib (Xl184) in Subjects With Radioiodine Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vegfr-Targeted Therapy · 2023 | Their institution | $4,800 |
| ABBVIE INC. · A Study of the Safety, Tolerability and Pharmacokinetics of Abbv-368 As A Single Agent and Combination in Subjects With Locally Advanced Or Metastatic Solid Tumors · 2023 | Their institution | $2,560 |
| Merck Sharp & Dohme LLC · An Open-Label Phase 1b,2 Study To Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-Pretreated, Recurrent,Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinomaallogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes Ata129 in Combination With Checkpoint Inhibitor Pembrolizumab in Patients With Advanced Platinum-Resistant Or Refractory Ebv-Associated Nasopharyngeal Carcinoma · 2023 | Their institution | $2,347 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l H&N Metastatic Nivo Chemo - An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin+Fluorouracil) As First Line Therapy in Recurrent Or Met · 2022 | Their institution | $2,036 |
| E.R. Squibb & Sons, L.L.C. · Ph III 1l H&N Metastatic Nivo Chemo - An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin+Fluorouracil) As First Line Therapy in Recurrent Or Metast · 2022 | Their institution | $1,280 |
| Merck Sharp & Dohme LLC · An Open-Label Phase 1b,2 Study To Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-Pretreated, Recurrent,Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinomaallogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes Ata129 in Combination With Checkpoint Inhibitor Pembrolizumab in Patients With Advanced Platinum-Resistant Or Refractory Ebv-Associated Nasopharyngeal Carcinoma · 2021 | Their institution | $784 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1588726558
- Licence
- CA C52711, MD D0041607California C52711: Current · expires 2026-11-30
- Trained
- Harvey Medical College
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Medical oncology (207RX0202X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2006-12-15
- NPI last updated
- 2024-04-28
- NPI record certified
- 2024-04-28
This is when the NPI record was last certified, not a medical board exam.